Jornal Vascular Brasileiro
https://jvascbras.org/article/doi/10.1590/S1677-54492007000300015
Jornal Vascular Brasileiro
Case Report

Doença arterial obstrutiva periférica agravada pela utilização de gemcitabina para tratamento de neoplasia pancreática: relato de caso e revisão da literatura

Peripheral obstructive arterial disease worsened by use of gemcitabine for the treatment of pancreatic cancer: case report and review of the literature

Eduardo Lichtenfels; Telmo Pedro Bonamigo; Vinícius C. Pires; Márcio Luis Lucas; Daiane Schlindwein

http://dx.doi.org/10.1590/S1677-54492007000300015 J Vasc Bras, vol.6, n3, p.293-296, 2007
PDF Português
PDF English
SciELO
Downloads: 0
Views: 1229

Resumo

Este estudo tem por objetivo relatar um caso de isquemia crítica de membro inferior associada a quimioterapia com gemcitabina. O relato descreve o caso de um paciente de 68 anos submetido a duodenopancreatectomia devido a tumor no pâncreas. Um mês depois da operação, o paciente realizou quatro sessões de quimioterapia com gemcitabina, durante um mês. Após 30 dias, o paciente desenvolveu sintomas de doença arterial obstrutiva periférica, e duas semanas depois, isquemia crítica do membro inferior direito. O exame por imagem demonstrou doença arterial difusa associada à oclusão femoropoplítea com reenchimento distal precário. O paciente foi submetido a uma tentativa de revascularização que, devido às condições locais, foi malsucedida, resultando na amputação do membro no nível da coxa.

Palavras-chave

Quimioterapia, trombose, neoplasias

Abstract

We report a case of lower limb critical ischemia associated with chemotherapy with gemcitabine. This report presents a case of a 68-year-old man who underwent pancreatoduodenectomy due to pancreas tumor. One month later, the patient was submitted to four chemotherapy sessions with gemcitabine for 1 month. In addition, 30 days later he developed symptoms of peripheral arterial obstructive disease, and critical ischemia of the right lower limb 2 weeks later. An imaging study showed diffuse arterial disease associated with femoropopliteal occlusion and poor distal bed. The patient was submitted to a revascularization procedure, which was unsuccessful due to local conditions, resulting in above-knee amputation.

Keywords

Chemotherapy, thrombosis, neoplasms

References

Barceló R, López-Vivanco G, Mañé JM, Rubio I, Muñoz A, Fernández R. Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: description of four cases. Ann Oncol.. 2000;11:1191-4.

McDonald GB, Hinds MS, Fisher LD. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med.. 1993;118:255-67.

Wall JG, Weiss RB, Norton L. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a cancer and leukemia group B study. Am J Med.. 1989;87:501-4.

Hansen SW, Olsen N, Rossing N, Rorth M. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol.. 1990;1:289-92.

Mathews J, Goel R, Evans WK, Shamji F, Stewart DJ. Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer. Cancer Chemother Pharmacol.. 1997;40:19-22.

Vos AH, Splinter TA, van der Heul C. Arterial occlusive events during chemotherapy for germ cell cancer. Neth J Med.. 2001;59:295-9.

Burstein HJ. Side effects of chemotherapy. J Clin Oncol.. 2000;18:693-4.

Castellano D, Hitt R, Cortés-Funes H, Romero A, Rodriguez-Peralto JL. Side effects of chemotherapy. J Clin Oncol.. 2000;18:695-6.

Attar EC, Ervin T, Janicek M, Deykin A, Godleski J. Side effects of chemotherapy. J Clin Oncol.. 2000;18:697-8.

Voorburg AM, van Beek FT, Slee PH, Seldenrijk CA, Schramel FM. Vasculitis due to gemcitabine. Lung Cancer. 2002;36:203-5.

Içli F, Karaoguz H, Dinçol D. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587-93.

Gerson R, Serrano A, Flores F, Villalobos A. Gemcitabine in advanced cancer: Phase 1 study. Rev Inst Nac Cancerol. 1998;44:72-6.

Weltman E, Salvajoli JV, Hanriot RM. Radioterapia em adenocarcinoma de pâncreas. Rev Assoc Med Bras.. 2002;48:118-28.

Cantwell BM, Mannix KA, Roberts JT, Ghani SE, Harris AL. Thromboembolic events during combination chemotherapy for germ cell-malignancy. Lancet. 1988;2:1086-7.

Hall MR, Richards MA, Harper PG. Thromboembolic events during combination chemotherapy for germ cell malignancy. Lancet. 1988;2:1259.

Weijl NI, Rutten MF, Zwinderman AH. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol.. 2000;18:2169-78.

Bauer KA, Levine M. Evaluation and management of the cancer patient with thrombosis. ASCO Educational Book. 1999:223-33.

Aapro MS, Martin C, Hatty S. Gemcitabine: A safety review. Anticancer Drugs. 1998;9:191-201.

Dobbie M, Hofer S, Oberholzer M, Herrmann R. Veno-occlusive disease of the liver induced by gemcitabine. Ann Oncol.. 1998;9:681.

Gietema JA, Groen HJ, Meijer S, Smit EF. Effects of gemcitabine on renal function in patients with non-small-cell lung cancer. Eur J Cancer. 1998;34:199-202.

Nackaerts K, Daenen M, Vansteenkiste J, Vandevelde A, Van Bleyenbergh P, Demedts M. Hemolytic-uremic syndrome caused by gemcitabine. Ann Oncol.. 1998;9:1355.

Tempero MA, Brand R. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1998;82:1800-1.

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
5ddec1760e882527187279a1 jvb Articles
1677-7301 (Electronic)
J Vasc Bras ©2024 All rights reserved.

J Vasc Bras

Share this page
Page Sections